

Title	PAR/RFA #	Description	Earliest Submission date	Expiration Date/Deadline	Eligibility	Budget	link
Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)	PAR-20-109	The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues <i>in vivo</i> .	3/5/2020	1/6/2022		Total funding support (direct costs, indirect costs, fee) normally may not exceed \$252,131 for Phase I awards and \$1,680,879 for Phase II awards.	https://grants.nih.gov/grants/guide/pa-files/PAR-20-109.html
Request for Information: Seeking Input from Cohort and Biorepository Researchers on Liquid Biopsy Studies for Early Cancer Detection	NOT-CA-22-010	This Request for Information is to solicit input on the availability of pre-diagnostic biospecimen collections which may be used for liquid biopsy studies of early cancer detection and assess interest in participating in a collaborative workshop on evaluation of cancer early detection biomarkers.	11/10/2021	1/15/2022			https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-010.html
Request for Information: Seeking Input from Technology Developers on Liquid Biopsy Studies for Early Cancer Detection	NOT-CA-22-011	This Request for Information is to solicit input about technologies which may be used for liquid biopsy studies of early cancer detection and assess interest in participating in a collaborative workshop on evaluation of cancer early detection biomarkers.	11/10/2021	1/15/2022			https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-011.html
Cellular Senescence Network: Technology Development and Application in Human Systems (UG3/UH3 Clinical Trial Not Allowed)	RFA-RM-22-004	The purpose of this FOA is to solicit applications for the development of novel, untested analytics and technologies to identify and map senescent cells in human tissues at high resolution. - pre-application webinar Dec 2nd https://grants.nih.gov/grants/guide/notice-files/NOT-RM-22-004.html	12/17/2021	1/19/2022		Applications should not exceed \$400,000 in direct costs per year during the UG3 phase and \$550,000 in direct costs per year during the UH3 phase.	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-004.html
Cellular Senescence Network: Murine Tissue Mapping Centers (U54 - Clinical Trial Not Allowed)	RFA-RM-22-003	The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) within the Cellular Senescence Network (SenNet) to build an atlas of cellular senescence in mice. - pre-application webinar Dec 2nd https://grants.nih.gov/grants/guide/notice-files/NOT-RM-22-004.html .	12/20/2021	1/20/2022		Application budgets are not limited but need to reflect the actual needs of the proposed project.	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-003.html
Cellular Senescence Network: Technology Development and Application in Murine Systems (UG3/UH3 Clinical Trial Not Allowed)	RFA-RM-22-005	The purpose of this FOA is to solicit novel analytics and technologies to identify and map senescent cells in murine tissues at high resolution. Pre-application webinar Dec 2nd https://grants.nih.gov/grants/guide/notice-files/NOT-RM-22-004.html	12/20/2021	1/20/2022		Application budgets are not limited but must reflect the actual needs of the proposed project. Applications should not exceed \$350,000 in direct costs per year during the UG3 phase and \$500,000 in direct costs per year during the UH3 phase.	https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-005.html
Biomedical Data Repository (U24 - Clinical Trials Not Allowed)	PAR-20-089	This funding opportunity announcement is designed to support biomedical data repositories. Biomedical data repositories under this announcement should have the primary function to ingest, archive, preserve, manage, distribute, and make accessible the data related to a particular system or systems.	8/25/2020	5/9/2023		The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NINDS intends to support up to 2 awards per fiscal year in FYs 2021, 2022, and 2023.	https://grants.nih.gov/grants/guide/pa-files/PAR-20-089.html
Biomedical Knowledgebase (U24 - Clinical Trials Not Allowed)	PAR-20-097	This funding opportunity announcement is designed to support biomedical knowledgebases. Biomedical knowledgebases under this announcement should have the primary function to extract, accumulate, organize, annotate, and link growing bodies of information related to core datasets.	8/25/2020	5/9/2023		Application budgets are not limited but need to reflect the actual needs of the proposed project.	https://grants.nih.gov/grants/guide/pa-files/par-20-097.html
Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)	PAR-21-253	The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease.	9/20/2021	10/20/2023		Application budgets are not limited, but need to reflect the actual needs of the proposed project.	https://grants.nih.gov/grants/guide/pa-files/par-21-253.html
NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)	PAR-22-065	This Funding Opportunity Announcement (FOA) encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base	5/14/2022	6/15/2024	Only those resources with technical capabilities that enable research activities within the program areas supported by NIGMS will be supported. Resources that support clinically-oriented research must be within one of the Institute's areas of clinical research focus . Resources that collect, maintain and distribute clinical samples (biobanks) or stand-alone data resources and databases will not be supported by this FOA. Contacting the Scientific/Research staff in advance of application submission is strongly recommended. Applications that do not adhere to the eligibility criteria will not be reviewed.	Application budgets are not limited but need to reflect the actual needs of the proposed project.	https://grants.nih.gov/grants/guide/pa-files/PAR-22-065.html

Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed)	PAR-21-226	This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that support biomedical and bio-behavioral research.	8/5/2021	9/6/2024	Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.	According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed \$259,613 for Phase I awards and \$1,730,751 for Phase II awards.	https://grants.nih.gov/grants/guide/pa-files/PAR-21-226.html
Notice of Special Interest (NOSI): Using the Collaborative Cross (CC) Mouse Model for Immunoregulatory and Infectious Disease Research	NOT-AI-21-071	Use mouse lines from the Collaborative Cross (CC) and recombinant inbred intercrosses of CC lines (CC-RIX) to more faithfully reproduce human immune responses and to advance understanding of the host genetics involved in immune regulation and function. Screen CC mouse lines to identify and characterize lines suitable for specific studies and disease models within the mission of NIAID (e.g., fundamental immunology, immune-mediated diseases, infectious diseases).	10/5/2021	9/8/2024			https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-071.html
Ultra-Rare Gene-based Therapy (URGenT) Network Resource Access (X01, Clinical Trial Not Allowed)	PAR-22-028	The purpose of this FOA is to provide investigators with a mechanism to access contract research/medical organizations (CROs/CMOs) and subject matter experts (SMEs) within the NINDS Ultra-Rare Gene-based Therapy (URGenT) Network to support planning, manufacturing, and limited nonclinical therapeutic development efforts.	11/22/2021	10/1/2024		Not Applicable; funds are not awarded via the X01 mechanism.	https://grants.nih.gov/grants/guide/pa-files/PAR-22-028.html

Updated 12/6/21